Feline Saddle Thrombus-Associated Acute Kidney Injury

Feline Saddle Thrombus-Associated Acute Kidney Injury (FST-AKI) refers to the acute deterioration of renal function that occurs secondary to aortic thromboembolism (ATE) in cats, a condition in which a thrombus lodges at the aortic trifurcation ("saddle thrombus"), obstructing blood flow to the caudal aorta and its branches, including the renal arteries or their collateral supply. While the classic clinical presentation of feline ATE centers on acute hindlimb paralysis and ischemic myopathy, a subset of affected cats simultaneously or subsequently develops acute kidney injury (AKI) due to renal hypoperfusion, ischemia-reperfusion injury, or direct thromboembolic occlusion of renal vasculature. This condition represents a severe, life-threatening complication of underlying cardiovascular disease—most commonly hypertrophic cardiomyopathy (HCM)—and carries a grave short-term prognosis. The combination of cardiac dysfunction, profound ischemia, metabolic derangement, and multi-organ involvement makes FST-AKI one of the most clinically challenging emergencies encountered in feline medicine.

Underlying Cardiac Disease and Thrombus Formation: Feline ATE arises predominantly in the context of structural heart disease, most commonly HCM, but also dilated cardiomyopathy (DCM), restrictive cardiomyopathy, and other cardiomyopathies. Atrial enlargement—particularly of the left atrium—promotes blood stasis, endothelial dysfunction, and a hypercoagulable state, collectively forming the "Virchow's triad" of thrombogenesis. Spontaneous echocardiographic contrast ("smoke") within the left atrium or left atrial appendage is a recognized precursor to thrombus formation. The resulting thrombus, once dislodged, travels through the aorta and most commonly lodges at the aortic trifurcation (the bifurcation into the external iliac arteries), producing the characteristic "saddle" configuration that obstructs blood flow to the caudal body.

Mechanisms of Acute Kidney Injury: AKI in this setting arises through several interrelated pathways:

1. ·

   Hemodynamic compromise: Obstruction of the distal aorta reduces cardiac output, causing systemic hypotension and decreased renal perfusion pressure. Cats with concurrent congestive heart failure further compromise renal blood flow through reduced forward cardiac output. Activation of the renin-angiotensin-aldosterone system (RAAS) in response to hypotension causes efferent arteriolar vasoconstriction, initially attempting to maintain glomerular filtration but ultimately contributing to ischemic tubular injury when hypotension is severe.

2. ·

   Direct renal arterial embolism: In some cases, smaller thromboemboli extend into or directly occlude renal arteries or interlobular vessels, causing focal or diffuse renal cortical ischemia and infarction. Both kidneys may be affected asymmetrically depending on embolic distribution.

3. ·

   Ischemia-reperfusion injury: Even after partial restoration of blood flow (spontaneously or with therapy), reactive oxygen species generated during reperfusion cause oxidative damage to tubular epithelium, exacerbating the initial ischemic insult. This mechanism is especially relevant in cats receiving thrombolytic therapy.

4. ·

   Myoglobinuria and tubular toxicity: Severe ischemic myopathy of hindlimb musculature leads to rhabdomyolysis and massive release of myoglobin. Myoglobin is filtered by the glomerulus and precipitates within tubular lumens, causing direct tubular toxicity and obstructive nephropathy—a significant contributor to AKI in this syndrome, analogous to crush-injury AKI in other species.

5. ·

   Hyperkalemia and metabolic acidosis: Ischemic tissue releases large quantities of intracellular potassium, lactic acid, and other metabolic byproducts. These systemically redistribute upon reperfusion, causing severe hyperkalemia and metabolic acidosis that further impair cardiac and renal function, potentially creating a lethal cycle.

6. ·

   Inflammatory mediators: Ischemic tissue releases prostaglandins, thromboxanes, cytokines, and other inflammatory mediators that promote systemic vasoconstriction, platelet aggregation, and additional microvascular thrombosis within the renal microvasculature, amplifying injury beyond the initial embolic event.

Risk Factors:

• ·Age (middle-aged to older cats, though young cats with congenital cardiomyopathy are also at risk)
• ·Male sex (over-represented in feline ATE)
• ·Breed predispositions for HCM (Maine Coon, Ragdoll, British Shorthair, Persian)
• ·Severe left atrial enlargement (left atrial-to-aortic ratio >2.0)
• ·Pre-existing chronic kidney disease (reduces renal reserve)
• ·Prior ATE episodes

Clinical Diagnosis: Diagnosis of FST-AKI is primarily clinical, based on the constellation of acute hindlimb paralysis, absent femoral pulses, cold and cyanotic extremities, concurrent oliguria/anuria, and signs of cardiac disease in a cat with appropriate signalment. The dramatic, acute onset and characteristic physical examination findings are usually sufficient to establish a working diagnosis of aortic thromboembolism at the bedside. Documentation of AKI requires laboratory confirmation.

Laboratory Findings:

Biochemistry Panel:

• ·BUN (Blood Urea Nitrogen): Markedly elevated — uremia reflects acute loss of glomerular filtration; BUN may rise precipitously within hours. Levels may exceed 100–200 mg/dL in severe cases.
• ·CREA (Creatinine): Markedly elevated — similarly reflects GFR loss; serial measurement every 6–12 hours is critical to track progression. SDMA may also be assessed where available.
• ·Potassium (K⁺): Severely elevated (hyperkalemia is common and life-threatening) — released from ischemic muscle; life-threatening cardiac arrhythmias (bradycardia, sine-wave pattern, ventricular fibrillation) can occur at levels >7–8 mEq/L.
• ·Phosphorus: Elevated — released from ischemic tissue; contributes to metabolic derangement.
• ·ALT (Alanine Aminotransferase): Often markedly elevated — reflects ischemic hepatopathy secondary to hypoperfusion and also muscle enzyme leakage (ALT has some muscle isoform activity in cats, though CK is more specific).
• ·CK (Creatine Kinase): Massively elevated — hallmark of ischemic myopathy; values may reach hundreds of thousands of U/L; useful marker for degree of muscle necrosis and myoglobinuria risk.
• ·AST: Elevated — reflects both hepatic and muscle injury.
• ·ALB (Albumin): Often low-normal to decreased — may reflect underlying chronic cardiac disease, third-spacing from heart failure, or concurrent hepatic dysfunction; hypoalbuminemia worsens renal function by reducing plasma oncotic pressure.
• ·GLOB (Globulin): Variable — may be elevated in chronic inflammatory/cardiac disease context.
• ·TBIL (Total Bilirubin): May be mildly elevated — ischemic hepatopathy or hemolysis.
• ·Glucose: Variable — may be elevated (stress hyperglycemia) or decreased in shock states.
• ·Lactate: Elevated (if measured) — reflects systemic anaerobic metabolism and tissue hypoperfusion; a useful real-time marker of perfusion and prognosis.

Hematology:

• ·HCT (Hematocrit): Variable — may be elevated initially (hemoconcentration from dehydration/shock) or low if underlying anemia; packed cell volume should be monitored serially.
• ·WBC (White Blood Cell Count): May be elevated — stress leukogram (neutrophilia, lymphopenia) is common; marked elevation may suggest concurrent infection or severe systemic inflammation.
• ·PLT (Platelets): Variable — thrombocytopenia may be present due to platelet consumption in thrombus formation; thrombocytosis is paradoxically possible as a reactive phenomenon. Coagulation panel abnormalities (prolonged PT, aPTT, elevated D-dimers, fibrinogen changes) consistent with disseminated intravascular coagulation (DIC) may occur in severe cases.

Urinalysis:

• ·Urine specific gravity: Isosthenuric or minimally concentrated (1.008–1.015) — loss of concentrating ability is an early indicator of tubular dysfunction.
• ·Proteinuria: May be present (tubular damage, glomerular hyperfiltration injury).
• ·Casts: Granular or pigment (myoglobin) casts in urine sediment are characteristic and confirm tubular injury from myoglobinuria.
• ·Hematuria/myoglobinuria: Urine may appear dark red-brown without red blood cells on sediment, consistent with myoglobin pigmenturia — a critical finding supporting rhabdomyolysis-associated AKI.

Acid-Base:

• ·Blood gas analysis: Metabolic acidosis (decreased bicarbonate, low pH) — essential to assess severity; guides bicarbonate therapy decisions.

Imaging:

• ·Echocardiography: Essential — identifies underlying cardiomyopathy, characterizes degree of left atrial enlargement, may directly visualize left atrial thrombus; assesses ventricular function and presence of pericardial/pleural effusion. LA:Ao ratio provides prognostic information.
• ·Thoracic radiography: Identifies cardiomegaly, pulmonary edema, or pleural effusion confirming congestive heart failure.
• ·Doppler ultrasonography: Absence of femoral arterial flow confirmed by Doppler; abdominal vascular ultrasound may demonstrate the thrombus within the distal aorta.
• ·Abdominal ultrasonography: Renal size, echogenicity, corticomedullary distinction, and Doppler assessment of renal blood flow; may reveal hyperechoic cortices indicating acute ischemic injury or infarcts. In acute AKI, kidneys may appear normal or mildly enlarged with reduced or absent blood flow on color Doppler.
• ·CT angiography: Gold standard for visualizing thrombus location and extent, as well as renal arterial occlusion, though often impractical in critically ill, hemodynamically unstable cats.

Staging AKI: The IRIS (International Renal Interest Society) AKI staging system can be applied based on creatinine level, urine output, and need for renal replacement therapy, helping guide management intensity and prognosis:

• ·Stage I–II: Mild-moderate creatinine elevation, some urine output
• ·Stage III–V: Severe azotemia, oliguria/anuria, requiring intensive intervention or dialysis consideration

Emergency Stabilization (Priority):

Treatment must address both the thromboembolic event and the associated AKI simultaneously. Cats with FST-AKI are critically ill and require immediate, intensive care.

1. Cardiovascular Stabilization and Pain Management:

• ·Analgesia: Opioid analgesics (e.g., buprenorphine 0.01–0.02 mg/kg IV/IM/OTM, or methadone, or hydromorphone) are essential for managing the severe ischemic pain; adequate pain control also reduces catecholamine-driven vasoconstriction and cardiac stress.
• ·Oxygen supplementation: Provided via flow-by, mask, or oxygen cage to address concurrent respiratory compromise; particularly important in cats with pulmonary edema.
• ·Management of congestive heart failure: Furosemide (1–2 mg/kg IV) for acute pulmonary edema/pleural effusion; caution is required as diuresis can worsen renal perfusion in the context of AKI and hypovolemia. Thoracocentesis for significant pleural effusion.

2. Management of Life-Threatening Hyperkalemia:

• ·Calcium gluconate (10%): 0.5–1.0 mL/kg IV slowly over 10–15 minutes — cardioprotective; stabilizes myocardial membrane without lowering potassium; indicated when ECG changes (bradycardia, widened QRS, absent P waves) are present.
• ·Regular insulin + dextrose: 0.25–0.5 IU/kg insulin IV with 2 g dextrose per unit of insulin — drives potassium into cells; monitor blood glucose closely.
• ·Sodium bicarbonate: 1–2 mEq/kg IV slowly — corrects acidosis and promotes intracellular potassium shift; indicated when pH <7.1 and in conjunction with other measures.
• ·Continuous ECG monitoring is mandatory throughout treatment.

3. Antithrombotic Therapy:

• ·Unfractionated heparin (UFH): 200–300 IU/kg IV loading dose, followed by 150–200 IU/kg IV or SC every 4–6 hours — does not dissolve existing thrombus but prevents further thrombus propagation and new embolic events; titrated to target aPTT 1.5–2× baseline. Particularly important for preventing recurrence.
• ·Low molecular weight heparin (LMWH): Dalteparin (100 IU/kg SC q12h) or enoxaparin (1 mg/kg SC q12–24h) — alternative or adjunct to UFH; more predictable bioavailability in cats.
• ·Thrombolytic therapy (tissue plasminogen activator, tPA): Streptokinase and recombinant tPA have been used in research and clinical settings to lyse the existing thrombus. While restoration of blood flow may be achieved, thrombolysis carries high risks of hemorrhagic complications, reperfusion injury, fatal hyperkalemia upon reperfusion of ischemic limbs, and is associated with very high procedural mortality in clinical feline patients. Its use remains highly controversial and is generally not recommended in most clinical settings; the risk-benefit ratio is unfavorable in the majority of affected cats.
• ·Clopidogrel: 18.75 mg per cat PO q24h — antiplatelet agent; primary role is in long-term secondary prevention rather than acute management; begin once the cat can tolerate oral medications.
• ·Aspirin: Low-dose (5 mg/cat q72h) — antiplatelet therapy for long-term prevention; less preferred over clopidogrel based on current evidence.

4. Renal-Specific Management (AKI):

• ·Fluid therapy: Judicious IV fluid administration (lactated Ringer's solution or 0.9% NaCl) to maintain renal perfusion pressure while avoiding fluid overload in a cat with underlying cardiac disease. This represents one of the most challenging management decisions in FST-AKI. Target mean arterial pressure >60 mmHg. Avoid sodium-containing fluids if severe hypernatremia; avoid potassium-containing fluids if hyperkalemia is present.
• ·Urine output monitoring: Place urinary catheter for strict input/output monitoring. Target urine output >1–2 mL/kg/h.
• ·Diuretics for oliguria: Once euvolemia/normovolemia confirmed, furosemide constant-rate infusion (0.25–1 mg/kg/h CRI) or mannitol (0.25–0.5 g/kg IV over 15–20 minutes) may be cautiously trialed to convert oliguria to non-oliguria; neither improves GFR but may improve tubular flow.
• ·Dialysis: Peritoneal dialysis or hemodialysis may be considered at referral facilities for cats with severe refractory oliguria/anuria, severe uremia (BUN >80–100 mg/dL), or intractable hyperkalemia not responsive to medical management; availability is limited in general practice.

5. Nutritional Support:

• ·Assisted feeding (esophagostomy/nasogastric tube) once stabilized — uremic cats are often anorexic; adequate caloric intake supports tissue repair and recovery.
• ·Phosphorus restriction if hyperphosphatemia is significant.

6. Monitoring:

• ·Serial BUN, creatinine, electrolytes, and blood gas every 6–12 hours in acute phase.
• ·ECG monitoring for cardiac arrhythmias.
• ·Blood pressure monitoring (Doppler or oscillometric).
• ·Serial neurological assessment of hindlimbs for evidence of recovery or progression.
• ·Echocardiography to reassess cardiac function and guide ongoing cardiac management.

7. Euthanasia Consideration: Given the high mortality rate and significant suffering associated with this condition, quality-of-life discussions with owners should begin early. Euthanasia is a humane and frequently chosen option, particularly in cats with severe multi-organ failure, intractable pain, no urine output, or life-threatening concurrent congestive heart failure.

The prognosis for cats with aortic thromboembolism is grave overall, and the development of concurrent AKI worsens this prognosis considerably. Published survival statistics for feline ATE in general (not specific to FST-AKI as a defined entity) provide the best available framework:

Short-Term Mortality:

• ·Acute (in-hospital/peracute) mortality for feline ATE is reported to be high; a significant proportion of cats (estimated 30–70% in various clinical reports and reviews) die or are euthanized within the first 24–48 hours of presentation. The development of concurrent AKI, severe hyperkalemia, metabolic acidosis, and concurrent decompensated congestive heart failure each independently worsen short-term outcomes.
• ·Cats with anuric/oliguric AKI that does not respond to treatment within 24–48 hours carry a near-fatal short-term prognosis, as renal replacement therapy is not universally available and underlying cardiac disease typically precludes recovery.

Long-Term Survival (Survivors of Acute Episode):

• ·Among cats that survive the acute hospitalization, median survival times of approximately 2 months have been reported in some clinical series, reflecting the high rate of recurrence, underlying progressive cardiac disease, and re-embolization.
• ·Cats with bilateral hindlimb involvement have a poorer prognosis than those with unilateral involvement.
• ·Cats with underlying congestive heart failure at the time of ATE have significantly shorter survival times compared to those without concurrent CHF.
• ·Recurrence of ATE is common (estimated 30–75% in cats surviving long-term), and each subsequent event carries additional morbidity and mortality.
• ·A small subset of cats — particularly younger cats with unilateral involvement, preserved cardiac function, and no concurrent CHF — may achieve meaningful survival of >6 months to years with aggressive management and ongoing anticoagulation and cardiac therapy.

Prognostic Indicators (Negative):

• ·Anuria or severe oliguria unresponsive to treatment
• ·BUN >100 mg/dL, CREA >7–10 mg/dL at presentation
• ·Severe hyperkalemia (K⁺ >7.5 mEq/L) refractory to treatment
• ·Bilateral hindlimb paralysis with absent deep pain perception
• ·Hypothermia (rectal temperature <97°F / 36.1°C)
• ·Concurrent decompensated CHF
• ·LA:Ao ratio >2.0 on echocardiography
• ·Markedly elevated CK (>10,000 U/L) indicating severe myonecrosis and myoglobinuria risk
• ·Advanced IRIS AKI staging (Stage IV–V)

Note: Data on long-term prognosis specific to "FST-AKI" as a formally defined subentity are limited in current veterinary literature; the statistics above are extrapolated from broader feline ATE literature and general AKI outcome data in cats. No dedicated peer-reviewed survival studies specifically addressing the FST-AKI combination were identified in the references cited above, and clinicians should interpret these figures accordingly.

Primary Prevention (Preventing Initial ATE):

• ·Cardiac screening: Regular echocardiographic screening for cats of predisposed breeds (Maine Coon, Ragdoll, British Shorthair, Persian, Sphynx) beginning at 2–3 years of age and repeated every 1–2 years — identification of cardiomyopathy and left atrial enlargement before thrombus formation allows for early anticoagulant intervention.
• ·Anticoagulation in high-risk cardiac patients: Cats with documented severe left atrial enlargement (LA:Ao ≥1.5–2.0) or echocardiographic "smoke" should be placed on antiplatelet or anticoagulant therapy:
  • ·Clopidogrel (Plavix): 18.75 mg/cat PO q24h — the FATCAT study demonstrated superiority of clopidogrel over low-dose aspirin for ATE prevention in cats with HCM and left atrial enlargement; this is currently the preferred agent.
  • ·Low-dose aspirin: 5 mg/cat q72h — less effective than clopidogrel as primary prevention but may be used in resource-limited settings.
  • ·Rivaroxaban and other novel oral anticoagulants are under investigation in cats; clinical data are emerging but not yet definitive.
  • ·LMWH (dalteparin, enoxaparin): Used in some high-risk cats, particularly perioperatively or in hospitalized patients; subcutaneous administration limits long-term home use.
• ·Management of underlying cardiac disease: ACE inhibitors, beta-blockers (atenolol), or calcium channel blockers (diltiazem) as appropriate for the specific cardiomyopathy type and functional stage — reducing left atrial pressure and size through optimal cardiac management may decrease thrombogenic risk.
• ·Weight management: Maintenance of ideal body weight reduces cardiac workload in predisposed breeds.
• ·Stress reduction: Minimizing environmental stressors that can exacerbate cardiac disease and elevate heart rate.

Secondary Prevention (Preventing Recurrence After an ATE Episode):

• ·Long-term clopidogrel therapy (18.75 mg/cat q24h) is recommended for all cats surviving an acute ATE episode.
• ·Combination antiplatelet therapy (clopidogrel + aspirin) or heparin anticoagulation may be considered in cats with very high recurrence risk, though bleeding risk must be weighed.
• ·Serial echocardiographic monitoring (every 3–6 months) to assess progression of cardiac disease, left atrial size, and adjust therapy.
• ·Regular renal function monitoring (BUN, creatinine, SDMA, urinalysis) — cats surviving FST-AKI are at high risk for chronic kidney disease as a sequela of the ischemic insult; early identification of CKD allows dietary and medical intervention.
• ·Owner education regarding recognition of early signs of recurrence (sudden limb weakness, vocalization, cold extremities) for prompt emergency presentation.

Prevention of Myoglobinuric AKI Specifically:

• ·Rapid and aggressive IV fluid diuresis upon thrombus resolution or with any improvement in limb perfusion to flush myoglobin from renal tubules before precipitation occurs — this is a window of intervention that can mitigate AKI severity when recognized promptly.